The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1320
Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved calcitriol ointment (Vectical – Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.

MECHANISM OF ACTION — Calcitriol is a synthetic form of the active metabolite of vitamin D3. It has anti-proliferative, prodifferentiating and immunomodulating effects on human keratinocytes.1

CLINICAL STUDIES — In 2 randomized, doubleblind trials in a total of 839 patients with chronic mildto- moderate plaque psoriasis, patients applied calcitriol ointment or vehicle ointment twice daily for 8 weeks. Treatment success (minimal disease or clear at 8 weeks) occurred in 34.4% and 33.3% of patients with calcitriol in the 2 studies, and in 22.5% and 12.3% with the vehicle.2

No studies are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
Article code: 1320b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian